factually
Index/Topics/CDK4/6 Inhibitors in HR+/HER2- Advanced Breast Cancer

CDK4/6 Inhibitors in HR+/HER2- Advanced Breast Cancer

The use of CDK4/6 inhibitors, specifically abemaciclib, palbociclib, and ribociclib, in the treatment of HR+/HER2- advanced breast cancer, including their efficacy, toxicity, and real-world effectiveness.

Fact-Checks

1 result
Feb 5, 2026

compare the Familiarity and habit of Ribociclib, palbociclib and abemaciclib

Three orally administered CDK4/6 inhibitors—, and —are widely accepted first‑line partners to endocrine therapy in and have broadly similar efficacy for progression‑free survival in trials, though rea...